The LUX-LUNG 3 study [35], a multicenter, randomized, open-label phase III study compared afatinib with cisplatin plus pemetrexed in patients with lung adenocarcinoma, stage IIIb/IV harboring EGFR mutations [36, 37]. Here, EGFR is linked to lung adenocarcinoma.